AI supported in silico screening of chimeric antigen receptor therapy targets
Chimeric antigen receptor (CAR) cell therapy has achieved transformative clinical success through targeting of CD19 in refractory B cell malignancies, but extension of this strategy to solid tumors, other hematological malignancies, and autoimmune disease has exposed the complexity of target selection. Antigen abundance alone is not sufficient to define a suitable CAR target. Instead, therapeutic efficacy and safety are shaped by a broader set of molecular features, including isoform usage, subcellular localization, secretion, epitope stability, and the structural context in which antibody-derived binding domains engage their target. At the same time, advances in transcriptomics, structural biology, and artificial intelligence (AI)-enabled prediction now make it possible to assess many of these properties systematically. Here, we outline the principal molecular features that characterize effective and safe CAR targets and present a practical framework that integrates public datasets with computational and AI-based tools for their evaluation. Using HER2 as an illustrative case, we show how isoform-resolved expression, single-cell analyses, topology prediction, structure modelling, epitope mapping, and in silico binding analyses can reveal liabilities that are not captured by conventional target-expression screens alone. This framework provides a systematic strategy to prioritize targets and epitopes, guide preclinical investigation, and de-risk clinical translation. We anticipate that such integrative workflows will become increasingly important for moving CAR target discovery from descriptive expression analysis towards informed therapeutic design.